Clinical trials: Alzheimer Disease
Alzheimer Disease
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine following multiple dosing in patients with renal impairment and compare to those in healthy subjects
- Trial name
- NCT02340195
- Testing
- Idalopirdine (Lu AE58054) 60 mg
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
Semantic Recognition Task (SRT) in Alzheimer Disease
The goal of this study is to observe the outcomes of a semantic recognition task in Alzheimer Disease and discuss what this might add to clinical practice.
- Trial name
- SRT (NCT05711888)
- Testing
- Semantic Recognition Procedure
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Frail Elderly
Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults
The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment.
- Trial name
- COGFRAIL (NCT03129269)
- Testing
- MRI and PET scan
- Where
- France
- Volunteers
- 344 people
- Sponsor
- University Hospital, Toulouse
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study…
- Trial name
- LEADLTFU (NCT05400330)
- Testing
- LX1001
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lexeo Therapeutics
Alzheimer Disease, Alzheimer Dementia
Multimodal Ocular Imaging in Neurodegeneration
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are two of the most common types of age-related neurodegenerative disorders.
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
- Trial name
- NCT03699644
- Testing
- Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Healthy
A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK, study of the way a drug enters and leaves the blood and tissues over time) of single-ascending oral doses of JNJ-54861911 in healthy…
- Trial name
- NCT02180269
- Testing
- JNJ-54861911 (25 mg), JNJ-54861911 (50 mg), JNJ-54861911 (100 mg)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease
[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain…
- Trial name
- NCT06141356
- Testing
- [18F]Florbetazine ([18F]92), [11C]PIB
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Alzheimer's Disease, Dementia With Lewy Bodies
Imaging of Brain Amyloid Plaques in the Aging Population
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in…
- Conditions
- Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
- Trial name
- NCT00950430
- Testing
- Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
- Where
- United States
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Alzheimer Disease
Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging
The goal of this study is to improve the diagnosis of Alzheimer's disease (AD) at two different stages (MCI and dementia) in illiterate subjects, using FDG- fluorodeoxyglucose - and florbetapir F 18 -PET imaging.
- Trial name
- AVILL (NCT02494531)
- Testing
- Fluorodeoxyglucose-PET, florbetapir F 18-PET
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer's Disease
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug.
- Trial name
- NCT00842673
- Testing
- ST101
- Where
- 18 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Sonexa Therapeutics, Inc.
Alzheimer Disease
DORA and LP in Alzheimer's Disease Biomarkers
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
- Trial name
- NCT06274528
- Testing
- Lemborexant 10 mg, Lemborexant 20mg
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Mild Cognitive Impairment, Alzheimer Disease
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
The aim of the study is to investigate the effects of coenzyme Q10 supplementation (150 mg twice daily; 300 mg/day for 12 weeks) on coenzyme Q10 status, glucose parameters, BDNF, myokines, and cognitive function in patients with…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Hyperglycemia, Pre-sarcopenia
- Trial name
- NCT06040905
- Testing
- Coenzyme Q10
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chung Shan Medical University
Alzheimer Disease
Enteric Nervous System in Alzheimer Disease
The close homology between the central and enteric nervous systems suggests that a disease process affecting the central nervous system could also involve its enteric counterpart.
- Trial name
- ENTEROMA (NCT02841605)
- Testing
- Rectosigmoidoscopy with colonic biopsies, Colonoscopy with colonic biopsies
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Nantes University Hospital
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Coronary Artery Disease, Diabetes Mellitus, Type 2
PIPAF Platelets in the Pathogenesis of Ageing Associated Frailty
This is a prospective observational study aimed at testing the existence of an association between frailty, inflammatory status, and degree of platelet activation and reactivity in elderly subjects with type 2 diabetes or…
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Alzheimer Disease
- Trial name
- PIPAF (NCT05798637)
- Testing
- Standard of care
- Where
- 2 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Alzheimer's Disease
Evaluating Liraglutide in Alzheimer's Disease
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.
- Trial name
- ELAD (NCT01843075)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 204 people
- Sponsor
- Imperial College London
Dementia, Alzheimer's Disease
Volunteers Adding Life in Dementia: VALID
Older adults with Alzheimer's disease and other forms of dementia frequently develop challenging neuropsychiatric symptoms (NPS) as a result of their illness.
- Trial name
- VALID (NCT01715181)
- Testing
- Volunteer visits
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Queen's University
Alzheimer's Disease, Dementia
Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients
The primary aim is to determine whether Divalproex ER or one of the atypical antipsychotics is more effective improving dementia related behavioral symptoms in patients with dementia, and evaluate the impact of such improvements…
- Conditions
- Alzheimer's Disease, Dementia, Behavioral Symptoms
- Trial name
- NCT00375557
- Testing
- Divalproex ER, Quetiapine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.